Publication: Mouse model of cat allergic rhinitis and intranasal liposome-adjuvanted refined Fel d 1 vaccine
Issued Date
2016-03-01
Resource Type
ISSN
19326203
Other identifier(s)
2-s2.0-84961138850
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
PLoS ONE. Vol.11, No.3 (2016)
Suggested Citation
Natt Tasaniyananda, Urai Chaisri, Anchalee Tungtrongchitr, Wanpen Chaicumpa, Nitat Sookrung Mouse model of cat allergic rhinitis and intranasal liposome-adjuvanted refined Fel d 1 vaccine. PLoS ONE. Vol.11, No.3 (2016). doi:10.1371/journal.pone.0150463 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/41114
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Mouse model of cat allergic rhinitis and intranasal liposome-adjuvanted refined Fel d 1 vaccine
Other Contributor(s)
Abstract
© 2016 Tasaniyananda et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Cats (Felis domesticus) are rich source of airborne allergens that prevailed in the environment and sensitized a number of people to allergy. In this study, a mouse model of allergic rhinitis caused by the cat allergens was developed for the first time and the model was used for testing therapeutic efficacy of a novel intranasal liposome-entrapped vaccines made of native Fel d 1 (major cat allergen) in comparison with the vaccine made of crude cat hair extract (cCE). BALB/c mice were sensitized with cCE mixed with alum intraperitoneally and intranasally. The allergic mice were treated with eight doses of either liposome (L)- entrapped native Fel d 1 (L-nFD1), L-cCE), or placebo on every alternate day. Vaccine efficacy evaluation was performed one day after provoking the treated mice with aerosolic cCE. All allergenized mice developed histological features of allergic rhinitis with rises of serum specific-IgE and Th2 cytokine gene expression. Serum IgE and intranasal mucus production of allergic mice reduced significantly after vaccination in comparison with the placebo mice. The vaccines also caused a shift of the Th2 response (reduction of Th2 cytokine expressions) towards the non-pathogenic responses: Th1 (down-regulation of the Th1 suppressive cytokine gene, IL-35) and Treg (up-regulation of IL-10 and TGF-β). In conclusions, a mouse model of allergic rhinitis to cat allergens was successfully developed. The intranasal, liposome-adjuvanted vaccines, especially the refined single allergen formulation, assuaged the allergic manifestations in the modeled mice. The prototype vaccine is worthwhile testing further for clinical use in the pet allergic patients.